209 related articles for article (PubMed ID: 32671332)
1. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis.
Arvaniti P; Giannoulis G; Gabeta S; Zachou K; Koukoulis GK; Dalekos GN
JHEP Rep; 2020 Aug; 2(4):100123. PubMed ID: 32671332
[TBL] [Abstract][Full Text] [Related]
2. Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series.
Kolev M; Sarbu AC; Möller B; Maurer B; Kollert F; Semmo N
J Transl Autoimmun; 2023; 6():100189. PubMed ID: 36718275
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of mycophenolate mofetil
Dalekos GN; Arvaniti P; Gatselis NK; Gabeta S; Samakidou A; Giannoulis G; Rigopoulou E; Koukoulis GK; Zachou K
JHEP Rep; 2022 Dec; 4(12):100601. PubMed ID: 36411768
[TBL] [Abstract][Full Text] [Related]
4. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis.
Biewenga M; Heidt S; Vergunst M; Marijnissen CMJ; de Man RA; van der Eijk AA; van der Meer AJ; Trouw LA; van Hoek B
JHEP Rep; 2022 May; 4(5):100460. PubMed ID: 35368991
[TBL] [Abstract][Full Text] [Related]
5. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis.
Laschtowitz A; Zachou K; Lygoura V; Pape S; Derben F; Jaeckel E; Oller-Moreno S; Weidemann S; Krech T; Piecha F; Schön G; Liebhoff AM; Al Tarrah M; Heneghan M; Drenth JPH; Dalekos G; Taubert R; Lohse AW; Schramm C
JHEP Rep; 2021 Aug; 3(4):100321. PubMed ID: 34381983
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil as second line treatment in autoimmune hepatitis - A retrospective single center analysis.
Kolev M; Diem S; Diem L; Rodrigues SG; Berzigotti A; Stirnimann G; Semmo N
J Transl Autoimmun; 2022; 5():100172. PubMed ID: 36451933
[TBL] [Abstract][Full Text] [Related]
7. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study.
Jothimani D; Cramp ME; Cross TJ
J Clin Exp Hepatol; 2014 Sep; 4(3):221-5. PubMed ID: 25755564
[TBL] [Abstract][Full Text] [Related]
8. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis.
Hanouneh M; Ritchie MM; Ascha M; Ascha MS; Chedid A; Sanguankeo A; Zein NN; Hanouneh IA
Scand J Gastroenterol; 2019 Jan; 54(1):76-80. PubMed ID: 30650311
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum BAFF levels in patients with autoimmune hepatitis.
Migita K; Abiru S; Maeda Y; Nakamura M; Komori A; Ito M; Fujiwara S; Yano K; Yatsuhashi H; Eguchi K; Ishibashi H
Hum Immunol; 2007 Jul; 68(7):586-91. PubMed ID: 17584580
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features of 107 autoimmune hepatitis patients and 30 of them with AIH-primary biliary cirrhosis overlap syndrome].
Qiu DK; Li XM; Wei J; Ye LJ; Peng YS; Ma X
Zhonghua Gan Zang Bing Za Zhi; 2008 May; 16(5):367-71. PubMed ID: 18510851
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
[TBL] [Abstract][Full Text] [Related]
13. Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.
Piantoni S; Regola F; Masneri S; Merletti M; Lowin T; Airò P; Tincani A; Franceschini F; Andreoli L; Pongratz G
Front Pharmacol; 2021; 12():666971. PubMed ID: 34093196
[No Abstract] [Full Text] [Related]
14. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil.
Liberal R; Gaspar R; Lopes S; Macedo G
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101487. PubMed ID: 32651078
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and pathological characteristics and outcome of 46 children with autoimmune hepatitis].
Cao LL; Zhang M; Zhu SS; Dong Y; Xu ZQ; Chen DW; Wang LM; Wang FC; Gan Y; Yan JG; Wang P; Li AQ
Zhonghua Er Ke Za Zhi; 2019 Jan; 57(1):40-45. PubMed ID: 30630230
[No Abstract] [Full Text] [Related]
16. Systemic lupus erythematosus and autoimmune hepatitis overlap disease in a hospitalized systemic lupus erythematosus cohort.
Wang CR; Tsai HW; Wu IC
J Formos Med Assoc; 2024 Jun; ():. PubMed ID: 38851914
[TBL] [Abstract][Full Text] [Related]
17. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
Wolf DC; Bojito L; Facciuto M; Lebovics E
Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
[TBL] [Abstract][Full Text] [Related]
19. Use of oral vancomycin in children with autoimmune liver disease: A single centre experience.
Di Giorgio A; Tulone A; Nicastro E; Norsa L; Sonzogni A; D'Antiga L
World J Hepatol; 2021 Dec; 13(12):2113-2127. PubMed ID: 35070012
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment with Belimumab in a Patient with Refractory Systemic Lupus Erythematosus after Initiation of Hemodialysis: Considering the Synergistic Effect of Belimumab and Immunological Burn-Out Phenomenon in End-Stage Renal Disease Patients on Hemodialysis.
Karasawa K; Ogura S; Takabe T; Miyabe Y; Iwabuchi Y; Akiyama K; Sato M; Moriyama T; Uchida K; Nitta K
Blood Purif; 2022; 51(2):182-188. PubMed ID: 33895749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
